title: [Primary coronary angioplasty for myocardial infarction--the view of the cardiologic surgeon].
abstract: The aim of this article is not to present a general academic review on primary angioplasty in patients with ST-elevation myocardial infarction, but rather to focus on some practical points that directly concern cardiologists who perform primary percutaneous interventions in these patients. We detail recent data about the use of the radial artery approach, thromboaspiration, new oral inhibitors of P2Y12, selective use of anti-GPIIb/IIIa, high dose of peri-procedural statin therapy, choice of the best stent, and the best approach for treating non-culprit lesions in patients with multivessel coronary artery disease. The changes observed in the overall management of patients undergoing primary PCI for ST-elevation myocardial infarction are likely to have participated in the decrease in mortality observed in several registries. New European guidelines on the management of STEMI, taking into account these diverse aspects, have just been published.
authors.affiliation: Service de cardiologie, hôpital Jacques-Cœur à Bourges, 145, avenue François-Mitterrand, 18020 Bourges cedex, France. xavier.tabone@ch-bourges.fr
authors.forename: X
authors.initials: X
authors.lastname: Tabone
mesh_terms: D000077284:Abciximab; D000284:Administration, Oral; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D054855:Drug-Eluting Stents; D004562:Electrocardiography; D005062:European Union; D019317:Evidence-Based Medicine; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000008:administration & dosage*; D017534:Radial Artery; D016032:Randomized Controlled Trials as Topic; D058925:Receptors, Purinergic P2Y12 / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007140:Immunoglobulin Fab Fragments; C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D058925:Receptors, Purinergic P2Y12; D000077284:Abciximab